Research Articles

Why Gilead Is The Most Exciting Growth Opportunity In 2014

Chuck Carnevale - Friday, August 15, 2014

Introduction

Earnings drive stock price in the long run and Gilead Sciences Inc (GILD) is entering a remarkable period of what could only be called astounding future earnings growth.  This has not gone unnoticed by the market, as the stock price has been on a steady ascent for the past several months. 

Furthermore, there have been numerous articles published in the media discussing its future prospects and investment appeal.  Therefore, I will not rehash what has already been written about this potentially remarkable investment opportunity, but I will offer the following several links to articles I found most interesting:

Gilead: More Good News For This Biotech Juggernaut

Understanding The Excitement That Surrounds Gilead

A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval

Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year

With this article I will offer a comprehensive fundamental review that I believe supports my view that in spite of its recent price run-up, Gilead remains a reasonably valued and exciting opportunity for those investors seeking maximum capital appreciation.   However, I will qualify this position by stating that my view is long-term.  In other words, there is always the possibility that current price may retreat over the short-run.  But, in the long run earnings determine market price and I believe the future earnings potential of Gilead is clear and well-defined.

Short Company Description

The following short business description on Gilead Sciences Inc provided courtesy of S&P Capital IQ:

“Gilead Sciences, Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, and commercialization of medicines in areas of unmet medical need. The company has operations in North and South America, Europe and Asia-Pacific.

The company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection, oncology/inflammation and serious cardiovascular and respiratory conditions.

In the liver diseases area, the company received approval from the U.S. Food and Drug Administration (FDA) of new drug application (NDA) for Sovaldi (sofosbuvir 400 mg). Sovaldi is a once-daily oral nucleotide analog polymerase inhibitor for the treatment of HCV infection as a component of a combination antiviral treatment regimen.

The company also received approval of Tybost (cobicistat) and Vitekta (elvitegravir 85 mg and 150 mg), each a component of Stribild, from the European Commission. In the oncology/inflammation area, the company filed for FDA and European Medicines Agency (EMA) marketing approval of idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with refractory indolent non-Hodgkin’s lymphoma (iNHL) and relapsed chronic lymphocytic leukemia (CLL). The company also continued to advanced research and development pipeline, with approximately 200 active clinical studies in 2013, of which approximately 60 were in Phase 3 clinical trials.”

Earnings Operating History

Up through 2013 Gilead was a consistently fast-growing biotechnology company averaging 42.9% per annum earnings growth.  However, as the following graph reveals, earnings growth had significantly slowed down since 2011.  This simultaneously led to a very low valuation.  On the other hand, the company’s stock price went on a rapid ascent in 2013, perhaps in anticipation of what was soon to come.

The following earnings only FAST Graphs™ on Gilead Sciences Inc illustrate the dynamic nature of a company’s earnings per share growth over different time periods.  Earnings growth is a dynamic calculation that varies when graphed from one timeframe to the next.  Consequently, it’s important to review several timeframes when evaluating a company’s historical earnings growth rate.  The following 15 calendar year, 10 calendar year, 7 calendar year and 5 calendar year graphs illustrate that although Gilead’s earnings growth has been consistently high over the years, it became explosive for 2014 and beyond (see earnings growth rates circled in yellow).  Note: growth rates include all estimates on the graph whether calendar or fiscal year. 

Earnings (Operating) History 15-Year

Earnings Operating History 10-Year

Earnings Operating History 7-Year

 

Earnings Operating History 5-Year

Current 15-Year Earnings and Price Correlated FAST Graph (with Normal P/E Ratio)

Current 10-Year Earnings and Price Correlated FAST Graph (with Normal P/E Ratio)

The key takeaway from the above earnings and price correlated graphs is that Gilead’s quantum leap in earnings growth has not yet been fully credited by the market.  Consequently, based on earnings expectations the stock appears to represent a compelling long-term investment.

15-Year Historical P/E Ratio Trend

The dark blue line reflects the fiscal year-end P/E ratio for Gilead Sciences Inc since 2008 (the right scale on the graph).  Clearly we see that Gilead’s P/E Ratio had been consistently dropping due to lower-than-average earnings growth, and then began rising again in 2012 and 2013.  However, the current explosion in earnings growth has once again brought the P/E Ratio on Gilead back into attractive valuation levels. 

Performance

Historical performance is functionally related to earnings growth achievement and starting valuation.  Consequently, when performance is properly measured, it is imperative that starting valuation be considered in conjunction with earnings (and dividends, if any) growth.

A high beginning valuation will reduce capital appreciation; a low beginning valuation will enhance capital appreciation.  When a company’s beginning valuation is in alignment with earnings, capital appreciation will be highly correlated with the company’s earnings growth rate.

15-Year Performance:  From Beginning Undervaluation

 7-Year Performance:  From Beginning Undervaluation

Earnings Forecasts

The “Estimated Earnings and Return Calculator” provides several specific future year’s earnings forecasts.  Specific near-term earnings forecasts (varies from two to four years) are provided to include the number of analysts reporting to S&P Capital IQ (yellow and green highlights).  Additionally, a long-term (three to five year) growth rate is also provided (orange highlights).  The specific number of analysts offering the long-term forecast is found in the FAST FACTS box (orange circle). 

Therefore, we highly recommend placing more credence on the near-term forecasts because they are likely to be more accurate.  Moreover, near-term forecasts tend to include a greater number of analysts in the consensus.

The graph below reports consensus earnings of $7.99 for fiscal 2014 according to 26 analysts reporting to S&P Capital IQ followed by $9.27 for fiscal 2015 according to 27 analysts and $10.00 for fiscal 2016 according to 23 analysts. These near-term forecasts for earnings growth indicate that Gilead is extremely undervalued at current levels.

Earnings Yield

Shareholders in publically traded companies, even though they are passive owners, can expect to be rewarded for their investment in proportion to the company’s earnings capacity.  Consequently, the earnings yield calculated from current and future (expected) earnings represents an important valuation consideration. 

Based on consensus estimates for 2014’s earnings, Gilead offers a current earnings yield of 8.3%.  However, since investors are always buying the future, the potential for high earnings yield is extremely robust, assuming earnings growth continues.

FUNdamentals:  A Deeper Look

Utilizing FUN Graphs (fundamental underlying numbers), the following important fundamental metrics and key ratios are offered to provide a deeper look into the company’s financial strength and current valuation.

Balance Sheet/Income Statement

The following balance sheet items are offered to reveal the financial health of the company.  They include assets per share (atps), cash and equivalents per share (cashps) and common equity or book value per share (ceps).

The following income statement item, revenues per share (revps) is offered to reveal the consistency of revenue growth.   

Gross and Net Profit Margins

Return on Assets, Equity and Invested Capital

Key Liquidity Ratios

Liquidity is an important consideration when evaluating a business.  The primary liquidity ratio that prudent investors look to is the current ratio (cr).

Additionally, the current ratio (cr) measures the company’s ability to retire its short-term liabilities (debt and payables) with its short-term assets (cash, inventory and receivables).  This important ratio is often referred to as the liquidity ratio and is a good indicator of a company’s ability to remain a going concern.  Gilead’s current ratio in the most recent quarter (MRQ) was a very healthy 2.5.  

Since many investors are concerned about price volatility, we have included five-year beta as an additional key ratio.  A beta of one or lower is considered ideal relative to risk.  On the other hand, a beta above one may also indicate the potential for above-market long-term performance.

Additional Key Valuation Ratios

Two important valuation ratios that investors consider are price to book value (pb) and price to sales (ps).  When considering both of these valuation ratios, the lower the better. 

Key Management Shareholder-Friendly Metrics

Many investors consider a company’s shareholder-friendliness based on its dividend policy and/or share buyback policy.  A consistent record of paying dividends, and better yet, increasing the dividend are considered positive attributes of management. 

However, many companies in the growth phase may consider it more profitable to retain their cash to fund growth.  Consequently, the lack of a dividend does not necessarily indicate that management is not shareholder-friendly.

Regarding share buybacks, they are considered friendly because they are anti-dilutive.  However, share buybacks should only be considered shareholder-friendly when management is buying back shares when stock price is sound or undervalued.

Summary and Conclusions

Investors are often deterred from investing in a stock when its price reaches an all-time high as it recently has in Gilead.  However, those same investors often fail to recognize that price and valuation are not the same.  In the case of Gilead, its current valuation remains quite attractive in spite of its recent price rise because of 2014’s explosive growth of earnings primarily attributed to the recent approval and sales of Sovaldi.  However, there are additional pipeline opportunities that suggest future earnings growth to continue, albeit at lower rates than 2014.  Consequently, based on valuation, Gilead appears to be a very attractive growth story for at least the next couple of years.  In other words, it’s not too late.

Moreover, most of the risks associated with Gilead’s future earnings power have been reduced based on recent reports and rulings.  The following articles from The Wall Street Journal, Barron’s and MarketWatch support this view:

Gilead Sciences: Arbitrator Removes ‘Doomsday Scenario’

English Drug Panel Backs Hepatitis Drug at a Discount

Gilead wins critical Sovaldi legal fight, Roche finds consolation

 Disclosure:  Long GILD at the time of writing.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.


Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”


Recent Posts


Tags

SHOO investing DLR EXLS SBRA SLGN ITW, UEPS Aristocrat ACOM stockResearchTool ARRS VFC SWK CPB PowerOfCompounding CAT MAIN CVX,SWK,MCD,TGT,PG,WMT,JNJ,MDT,AFT,T,ED K APEI BF.B Industrial C PCL MGA FAST ROST consumer X dividend paying BBBY CHD LQDT market NFLX POWR PBI AMG dividend-paying CIO LMT AAPL GT P ULTA HIBB ALB MNST CTL HNZ healthcare value trap SPY SUBX machinery due diligence HD SYNA ALTE OKS CE ANTM PCLN DividendIncome IBN LLY ONE OII GMCR GILD CSCO CR BAX capital appreciation IDA AFL PKG EMR Valuation CVX Market Outlook UNM FairValuation WRLD ETP ATW AVP SIG mid-cap DD MCD PortfolioDesign DDS TNC UNH fair value GES RMD MTW JKHY earnings CGY RS long-term growth HP ACI Utilities Sector VAL VZ ENDP BOBE investing for income dividend-growth BAP MDP DR HighQuality WWW PE DIS dividendpaying economy KFT JNJ Fundamentals market currents GE AFL,CVX,ED,JNJ,MCD,PG,SWK,T,WMT,TGT,ABM,AFL,BEN,BMS,CB,CBSH,CTBI stock Ratio PPL short ideas LO PFG SO DividendChampions RY T TEF CLX THFF UNP WHR macro OUTR ADM Yield CKSW FDO UTHR FLO WAG GrowthOriented rate of return DVA BHB AAP OGE UTX HON COH long-term RRC HII FAF LINE IR BCOR LOW MKC BMO TOT DTV TU TGT V BAC DORM SLW JWN marketvaluation MUR WU AKRX XEL SAM Stock Research Analysis NA investment POT DHR AVD SYT ITW TNGO CATY AMP Overvalued QCOM dividend income NROM true worth HSC ATHM GEOS long-term returns CLX,EMR AA HE InformationTech ETR LKQ EAT BWLD ESI BPL UN INT PRXL MYL COP M investing for total return DELL DOV CBU DNB dividend growth investing value investing value-oriented WSM SCHW MATW TWX US Economy ARLP WGL AIRM SILVER WMT,ROST,GIS,GE,JNJ,KO GOOG OHI,EPR,WPG,JLL SCL FF ACE GPCM ENSG RIMM HRS PRGO NSRGY HAS total return AEG RTN DGAS SHPG TEVA LL ECL CSX MNR DGX VMI interest rates GME ADP HCI WFC HSNI suvivorship basis MDT ORCL NVS Challengers DividendAristocrats OXY TEG: WEC: FRAN WVR Dividend Ideas LLL JWML.Y TSM MGEE NKE DECK AIG BANF PB BCE KMP JCI FBHS SHR high-yield MGRC ACQ InterestRates stock analysis MO long-term investing REXX KO,CLX,CELG,JCP,GT,MSI,PEP,ED CNC DOM dividend paying stocks CRLI SoundValuation INFY GPI GOLD PEG stock research tool MELI BDX FUL THO WEC stocks MAN XRX BRLI JCOM BHP AMGN CELG SNCR Dividend Champions DLPH VRX fast-growing LTM CBRL CERN MA ACR GNTX CNSL EE AAN portfolio WY CTAS AEP ZBRA SAVE ACN EK RBC AZO CLF dividendGrowth ZUMZ fastgraphs TROW technology MTZ CHS VTR EMC INGR MNK TGH RJF IBM DAN TMP DRI BMS ABC BEAV SNI POR BEN VVC CVS CXRX ORI RAI PCP THC MSCC BMTC DTEGY CLR GOOGL TAC CM R FTI,HTZ BKH intrinsicvalue LEN best-of-breed GAS JPM Utilities COO Contenders KO biotechnology UHS CINF TGI AB earnings growth RSO TIS cyclical HCA ABM AGLP WBA KSS Buffett OSIS KALU MSA TICC FC BRS SXL NOC NPM WMT CFR WST AET CSL MCHP STE ADT growth O diversified machinery RSG,RTN FAST Graphs utility stocks WASH PII F CAPE CBI COST ETN DFS TWGP EBAY JAZZ FISV dividend growth CTSH ICLR DMRC CTG FB HCBK blue chip food service PNR BCR GWW HBI COL MHP banks ITC SIVB Macro view BG GIS BigFive,Canadian EWBC UL FinancialSector value THRM cash flows ASNA intrinsic value,stocks,earnings,fundamentals,stock research tool,due diligence CTCM FL PNW PM BBY RatofReturn IPAR SCG Champions LXU KCAP BWP PRAA DPS OKE XOM BIDU NEE CL PAG ED SBR intrinsic value Share Buybacks MRK TIF KMB STMP APH TUP PPG ROSE HSY dividends,earnings growth DTE OZRK CB ED:SCG MHS AXP AM TRV dividends BLL ACM SFG INWK AMZN free cash flow WFM Telecommunications CACI NSR AFAM hyper growth stocks TSCO Materials AFSI JRN AFG BIIB suvivorship SU FOSL biotech NC HCN MMM EPHC cashflow DRC MNTX PDFS NSC BMRC D DRIP SJM TE fundamental stock research tool EXC BOKF VRTU QCOR FRED AMT NLY PG FLIC investing for income,growth and income mid-sized AMCX PSX SBUX DE CAH CanadianBanks CRI Consumer discretionary CMI MPW DOW ODFL long RRD blue-chip ECHO long ideas AMAG SHW AGN above-average CAM LH LZB FCFS ABT AZZ MIDD fair valuation WLP GPC SEIC stock research market timing GD MCY WIN regional banks 3NSRGY BOFI CTBI NTES AMBN SWFT EnergySector SNH retirement DKS KMT CACC MCK VCO ANDE PNRA ConsumerDiscretionary FDX HRL BNS SON REITs BA HCP INTC growth stocks utility EMR, MMM PE Ratio CASY POM FairlyValued ESRX APD DollarCostAverging SWKS ABBV CPN act KR BR JSFT URI PNM cash flow MSFT HOG BLK HGT PEP RDS.A GLT RCII sell NOG PFE treasury Bond,TGT,UTX SPLS MAT EV Aristocrats TXT BH SYY CTRX highqualityR FOMC GPS SRCE OHI AOS SYK CHE HPQ JOY RKT dividend beta IR, RSG FTR CCK BNS.

Archive

Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”